CD274 and urothelial carcinoma: This cohort is composed of patients with advanced urothelial carcinoma that received Atezolizumab, an anti-PD-L1 checkpoint inhibitor, and is ideally suited for our investigation given that pre-treatment samples were characterized by both RNA-seq and immunohistochemistry (Mariathasan et al., 2018).